NeuroProtectionLab is a multidisciplinary and highly motivated research group which members belong to different areas such as pharmacology, medicinal chemistry, biotechnology, bioinformatics, biochemistry, and medicine with the common purpose of finding innovative therapies for neurodegenerative diseases (NDDs), with special interest in Alzheimer’s disease, tauopathies and cerebrovascular diseases. To do this, we develop projects that range from medical chemistry (design and synthesis of molecular models) to the testing of models in animals, including the repositioning of drugs and the fine-tuning of new in vivo neurodegeneration drugs. Our projects focus on the following lines of research:
Primary culture of neurons from the mouse prefrontal cortex expressing the human tau protein with the P301L mutation. Blue: nuclei. Red: hyperphosphorylated tau at Ser202/Thr305. Green: hyperphosphorylated tau at Tyr18.
NDDs share common pathophysiological mechanisms such as aging, proteinopathy, oxidative stress, neuroinflammation, mitochondrial dysfunction, or intracellular calcium dyshomeostasis. At this point we are working at several levels:
For the search and identification of new therapies for NDDs, we are working in areas such as:
Image of mouse hippocampus injected with an adeno-associated particle expressing human tau protein with the P301L mutation. Blue: nuclei. Red: hyperphosphorylated tau at Ser202/Thr305. Green: hyperphosphorylated tau at Tyr18.
The NeuroProtectionLab group -directed by Dr. Manuela García López, Professor of Pharmacology at the Department of Pharmacology and Therapeutics- is part of: